SCHEDULE: Major Investor Cuts VOR Biopharma Stake to 23.3%

Reprogrammed Interchange LLC and Reid Hoffman reduced their beneficial ownership in VOR Biopharma Inc. to 23.3% following open market share sales.

Summary

• Reprogrammed Interchange LLC and Reid Hoffman, as Reporting Persons, filed an Amendment No. 4 to their Schedule 13D.
• The filing reports open market sales of VOR Biopharma Inc. common stock by Reprogrammed Interchange LLC.
• These sales, occurring between September 12, 2025, and October 3, 2025, decreased the Reporting Persons' beneficial ownership by more than one percent of the outstanding shares.
• The current aggregate beneficial ownership stands at 1,597,308 shares, representing 23.3% of the common stock.
• All share amounts and weighted average sale prices reflect a 1-for-20 reverse stock split of Vor Biopharma Inc. Common Stock, effective September 18, 2025.
• Sales during September 12-October 3, 2025, included 15,000 shares at $35.0811, 20,000 shares at $32.815, 22,363 shares at $30.8023, 1,400 shares at $39.1925, 32,451 shares at $39.828, and 7,901 shares at $37.832.
• Additional sales within the past 60 days (August 25-September 11, 2025) were also disclosed, totaling 252,277 shares at various prices ranging from $36.3019 to $42.3256.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant beneficial owner reducing their stake in the company, which can signal a lack of confidence or a strategic divestment. This action typically puts downward pressure on the stock price and investor sentiment.

Negatives

• A significant beneficial owner, Reprogrammed Interchange LLC, has reduced its stake in VOR Biopharma Inc. by more than one percent of the outstanding shares.
• The sales occurred over several dates, indicating a sustained reduction in exposure by a major investor.
• The weighted average sale prices for some recent transactions (e.g., $30.8023 on September 16, 2025) were lower than earlier sales in August, potentially indicating a declining price trend during the selling period.

Risks

• Significant selling pressure from a major investor could negatively impact the stock price.
• A reduction in stake by a prominent investor like Reid Hoffman might be perceived as a lack of confidence in the company's future prospects.

Future Outlook

NA

Industry Context

This filing reflects a significant investor's decision to reduce exposure to VOR Biopharma, a common occurrence in the volatile biopharma sector where investor sentiment can shift rapidly based on clinical trial results, regulatory approvals, or strategic pivots. Such a reduction by a prominent investor like Reid Hoffman could be watched closely by other institutional investors in the biopharma space.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on stock price due to a major investor reducing their stake.
• Potential Investors: Might view the reduction in ownership by a prominent investor as a cautionary signal, influencing investment decisions.

Key Dates

Recommendation

The continuous and significant reduction in stake by a major investor like Reprogrammed Interchange LLC, associated with Reid Hoffman, suggests a lack of conviction in VOR Biopharma's near-term prospects or a strategic exit. This action, especially following a reverse stock split, often signals potential future weakness and could lead to further selling pressure. A seasoned investor would likely interpret this as a negative indicator and consider reducing or exiting their position.

Keywords

VOR Biopharma, Reprogrammed Interchange LLC, Reid Hoffman, Schedule 13D/A, Beneficial Ownership, Share Sales, Reverse Stock Split, Biopharma, Investor Activity, Equity Stake